Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

639
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
639
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Profiling the tumor immunological status in Japanese solid cancers using the tumor immune status scoring algorithm.

Scientific reports·2026
Same author

Analysis of HLA class I allele genotypes and immune-related gene alterations in patients with pan-cancer using whole-exome and whole-genome sequencing.

Biomedical research (Tokyo, Japan)·2025
Same author

The antitumor mechanism of immuno-flap treatment in a rat model of head and neck cancer.

Cancer immunology, immunotherapy : CII·2025
Same author

Pancancer Landscape of Long Non-coding RNA Expression and Immune Status of the Tumor Microenvironment in Japanese Cancer Patients.

Anticancer research·2025
Same author

Impact of the PD-1/PD-L1 inhibitor SCL-1 on MDA-MB231 tumor growth in a humanized MHC-double knockout NOG mouse model.

Scientific reports·2025
Same author

Association of Epstein-Barr virus genomic alterations with human pathologies.

Blood·2025

Related Experiment Video

Updated: Aug 24, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

494

Development of Novel Small Antitumor Compounds Inhibiting PD-1/PD-L1 Binding.

Yasuto Akiyama1, Tadashi Ashizawa2, Akira Iizuka2

  • 1Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan; y.akiyama@scchr.jp.

Anticancer Research
|October 26, 2022
PubMed
Summary
This summary is machine-generated.

Researchers identified SCL-1, a novel oral small molecule that inhibits programmed death-1 (PD-1)/PD-ligand 1 (PD-L1) binding. This compound demonstrated significant antitumor effects in preclinical models, offering potential for cancer immunotherapy.

Keywords:
ADME evaluationELISA for inhibition of PD-1/PD-L1 bindingMHC-dKO NOG mouseSmall chemical compound libraryin silico screening

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.3K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.5K

Related Experiment Videos

Last Updated: Aug 24, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

494
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.3K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.5K

Area of Science:

  • Immunology
  • Pharmacology
  • Oncology

Background:

  • Current anti-programmed death-1 (PD-1)/PD-ligand 1 (PD-L1) antibody therapies for solid cancers have limitations.
  • Oral small molecule inhibitors targeting PD-1/PD-L1 offer improved bioavailability and potential advantages.

Purpose of the Study:

  • To screen and identify novel small molecule inhibitors of PD-1/PD-L1 interaction.
  • To evaluate the in vitro and in vivo antitumor activity of identified compounds.

Main Methods:

  • Screening of 67,395 compounds from the Shizuoka small compound library.
  • In vitro assays and absorption, distribution, metabolism, and excretion (ADME) scoring.
  • In vivo efficacy studies using a humanized NOG mouse model with PD-L1+ SCC-3 tumors.

Main Results:

  • Six potential PD-1/PD-L1 inhibitors were identified, with SCL-1 and SCL-2 selected for further study.
  • SCL-1 showed moderate PD-1/PD-L1 binding inhibition and significant antitumor effects in vivo, dependent on CD8+ T cell infiltration.
  • Pharmacokinetic studies confirmed good oral bioavailability and distribution for SCL-1.

Conclusions:

  • SCL-1 is a novel small molecule inhibitor of PD-1/PD-L1 binding.
  • SCL-1 demonstrates potent antitumor activity and favorable pharmacokinetic properties.
  • SCL-1 holds promise as an orally administered agent for cancer immunotherapy.